Debiopharm begins Phase II trial of alisporivir against Covid-19 in France
Swiss biopharmaceutical firm Debiopharm has started the dosing of the first patient in a Phase II proof-of-concept clinical trial of its antiviral alisporivir (Debio 025) for treating hospitalised Covid-19 patients.
REMD-377 topline results highlight the benefits of adjunct therapies in type 1 diabetes
REMD Biotherapeutics’ Phase II study of volagidemab has revealed improvements in glycemic control. The results revealed that volagidemab was associated with meaningful improvements in glycemic control, measured by haemoglobin A1c…